Survival of patients diagnosed with Cervical Cancer, clinical stages IIB-IIIA-IIIB. SOLCA - Cuenca. 2009 - 2013.

Original Research

Published

2020-04-30

How to Cite

Morocho Romero, K. A., Villavicencio Romero, E. J., Andrade Galarza, A. F., & Roldán Fernández, J. V. (2020). Survival of patients diagnosed with Cervical Cancer, clinical stages IIB-IIIA-IIIB. SOLCA - Cuenca. 2009 - 2013.: Original Research. Oncology Journal (Ecuador), 30(1), 53–65. https://doi.org/10.33821/472

Issue

Section

Original Articles

Authors

DOI:

https://doi.org/10.33821/472

Keywords:

Cervix Uteri, Uterine Cervical Dysplasia, Survival Analysis

Abstract

Introduction: The survival of patients with Cervical Cancer is influenced by the clinical stages of the disease and its histology. The objective of this study was to establish survival in a group of patients from an oncology center in Cuenca-Ecuador.

Methods: It is a descriptive, retrospective, analytical study, in which information was collected from the medical records and physical records of the SOLCA - Cuenca medical system to establish Survival during the period 2009-2013. Demographic and clinical variables are described ( Type of histology and stage), Survival is compared between patients with these variables.

Results: 150 cases were included, mean age of 57.1 ± 14.0 years. The most prevalent marital status was “married” n = 75/150 (50%), of urban origin n = 83/150 (55.3%) from the province of Azuay (48.0%). The most prevalent histological type was epidermoid cancer (92%), 60% in clinical stage IIB. Mortality of 7 cases. Overall Survival (OS) 57.6 months; with a SE of 0.88 and a 95% CI with a range of 55.9 to 59.4 months. OS in stage IIB was 58.4 months (SE: 0.91; 95% CI: 56.63 - 60.20). In stage IIIB it was 56.3 months (SE: 1.85; 95% CI: 52.71 - 59.96), no statistical difference was found (P = 0.45). OS was higher in squamous cell carcinoma (Mean: 58.2 months; SE: 0.79, 95% CI: 57.70 to 59.81) in relation to the adenocarcinoma variant (Mean: 50.08 months; SE: 6.26; 95% CI: 37.81 to 62.36), with statistical significance (P= 0.045).

Conclusion: Overall survival was 57.6 months, with a survival difference for histological type, the longest being for squamous cell carcinoma 8 months less for adenocarcinoma. There were no differences between survival between clinical stages IIB and IIIB

Downloads

Download data is not yet available.

Author Biographies

Andrés Fernando Andrade Galarza, pHD, Servicio de Oncología, Instituto del Cáncer- SOLCA, Cuenca.

Médico por la Universidad de Cuenca, Doutor em Medicina Ciencias Medicas por la Universidad Federal Do Rio Grande Do Sul (PHD).

José Vicente Roldán Fernández, Escuela de Medicina, Facultad de Ciencias Médicas, Universidad de Cuenca

Médico por la Universidad de Cuenca, Magíster en Investigación de la Salud.